Ad
related to: gefapixant for chronic cough
Search results
Results from the WOW.Com Content Network
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4] It was approved for medical use in the European Union in September 2023. [1]
The health regulator concluded the company's application for the drug, gefapixant, did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic ...
The U.S. Food and Drug Administration's (FDA) panel voted 12 to 1 against the late-stage data submitted by Merck for the drug gefapixant, which showed a small reduction in cough frequency compared ...
The panel will deliberate whether the data provided by Merck establishes that a small reduction in cough frequency with the use of gefapixant is clinically meaningful to patients. US FDA staff ...
ATC code R05 Cough and cold preparations is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup R05 is part of the anatomical group R Respiratory system ...
Showed that gefapixant could be used to treat some types of cough, making it the first new cough medicine in 50 years. [21] [22] Demonstrated that a blood test can be used to better diagnose pre-eclampsia. [23] [24]
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
Camlipixant is an investigational new drug that is being evaluated for the treatment of chronic cough. [1] It is a P2X3 receptor antagonist. [2] See also. gefapixant;
Ad
related to: gefapixant for chronic cough